CPT code 78072 identifies a specialized nuclear medicine procedure for parathyroid imaging that uses two different radiopharmaceuticals, SPECT imaging, and CT correlation to localize abnormal parathyroid tissue prior to surgery. This dual-tracer, multimodality approach improves anatomic localization and can include subtraction techniques to enhance detection. Nationally, 78072 is important for preoperative planning in primary and secondary hyperparathyroidism and impacts surgical workflow and imaging center utilization.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose and procedural components of 78072, common payer coverage considerations, expected sites of service, and operational implications for radiology and nuclear medicine practices. The publication also outlines benchmark themes such as utilization patterns, coding nuances for combined SPECT/CT studies, and relevant policy updates that influence prior authorization and medical necessity determinations.

This summary provides clinicians, billers, and policy analysts with the clinical context and payer landscape needed to understand where 78072 fits in the imaging pathway for parathyroid disease and what to expect from national payers regarding coverage and preoperative localization workflows.